{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:42:38Z","timestamp":1793824958449,"version":"4.6.1"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,10]]},"abstract":"<jats:p>Immune checkpoint inhibitors (ICIs) have revolutionized oncology, but are associated with immune-related adverse events. Clinically, pneumonitis is a well-recognized complication, but its histopathologic features are poorly understood. Institutional archives were searched for patients having ICI therapy and subsequent lung tissue sampling. After excluding infectious cases, 9 patients (5 women, median: 59\u2009y) were identified with clinically suspected ICI-related pneumonitis. Clinical history, imaging, and pathology slides were reviewed. Patients received pembrolizumab (6 cases), nivolumab (1), ipilimumab followed by pembrolizumab (1), or pembrolizumab followed by nivolumab (1); the latter experienced pneumonitis with both agents. Treatment duration ranged from 1 to 33 cycles (median: 8). Three patients received concurrent chemotherapy and 1 received radiation; the remainder received ICI monotherapy. Symptoms were nonspecific; 2 patients were asymptomatic. Thoracic imaging showed bilateral ground glass or nodular opacities in all cases, often with pleural effusion. Histologically, organizing pneumonia was seen in 7 patients, all with subclinical or mild disease, admixed with vague non-necrotizing airspace granulomas in 3 cases; all 6 patients with follow-up did well. One patient had acute fibrinous pneumonitis and 1 had diffuse alveolar damage; both died. All 9 cases showed foamy macrophages and pneumocyte vacuolization; 6 had rare eosinophils. ICI-related pneumonitis presents as bilateral ground-glass opacities or nodules, and usually manifests as organizing pneumonia histopathologically, often with vague non-necrotizing airspace granulomas. Foamy macrophages and pneumocyte vacuolization are characteristic and rare eosinophils are often seen. Less commonly, acute fibrinous pneumonitis or diffuse alveolar damage can occur, which may be fatal.<\/jats:p>","DOI":"10.1097\/pas.0000000000001298","type":"journal-article","created":{"date-parts":[[2019,6,3]],"date-time":"2019-06-03T18:20:50Z","timestamp":1559586050000},"page":"1331-1340","source":"Crossref","is-referenced-by-count":74,"title":["Clinical and Histopathologic Features of Immune Checkpoint Inhibitor-related Pneumonitis"],"prefix":"10.1097","volume":"43","author":[{"given":"Brandon T.","family":"Larsen","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Mayo Clinic, Scottsdale, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"June M.","family":"Chae","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuj S.","family":"Dixit","sequence":"additional","affiliation":[{"name":"Radiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas E.","family":"Hartman","sequence":"additional","affiliation":[{"name":"Radiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Peikert","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja C.","family":"Roden","sequence":"additional","affiliation":[{"name":"Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230922","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"R2-20230922","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"R3-20230922","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"R4-20230922","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1016\/j.jtho.2018.10.007","article-title":"Checkpoint inhibitor pneumonitis\u2014real-world incidence and risk","volume":"13","author":"Tay","year":"2018","journal-title":"J Thorac Oncol"},{"key":"R5-20230922","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1158\/2326-6066.CIR-16-0237","article-title":"Comprehensive meta-analysis of key immune-related adverse events from CTLA-4 and PD-1\/PD-L1 inhibitors in cancer patients","volume":"5","author":"De Velasco","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"R6-20230922","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.chest.2017.04.177","article-title":"Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer: a systematic review and meta-analysis of trials","volume":"152","author":"Khunger","year":"2017","journal-title":"Chest"},{"key":"R7-20230922","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1001\/jamaoncol.2016.2453","article-title":"Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis","volume":"2","author":"Nishino","year":"2016","journal-title":"JAMA Oncol"},{"key":"R8-20230922","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","article-title":"Pneumonitis in patients treated with anti-programmed death-1\/programmed death ligand 1 therapy","volume":"35","author":"Naidoo","year":"2017","journal-title":"J Clin Oncol"},{"key":"R9-20230922","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.jtho.2018.11.016","article-title":"Impact of checkpoint inhibitor pneumonitis on survival in NSCLC patients receiving immune checkpoint immunotherapy","volume":"14","author":"Suresh","year":"2019","journal-title":"J Thorac Oncol"},{"key":"R10-20230922","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jtho.2018.12.017","article-title":"Checkpoint inhibitor pneumonitis: too clinically serious for benefit","volume":"14","author":"Le","year":"2019","journal-title":"J Thorac Oncol"},{"key":"R11-20230922","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.3389\/fphar.2018.01430","article-title":"The relative risk and incidence of immune checkpoint inhibitors related pneumonitis in patients with advanced cancer: a meta-analysis","volume":"9","author":"Ma","year":"2018","journal-title":"Front Pharmacol"},{"key":"R12-20230922","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1016\/j.jtho.2018.08.2035","article-title":"Pneumonitis in non-small cell lung cancer patients receiving immune checkpoint immunotherapy: incidence and risk factors","volume":"13","author":"Suresh","year":"2018","journal-title":"J Thorac Oncol"},{"key":"R13-20230922","doi-asserted-by":"crossref","first-page":"e0160221","DOI":"10.1371\/journal.pone.0160221","article-title":"Adverse events associated with immune checkpoint blockade in patients with cancer: a systematic review of case reports","volume":"11","author":"Abdel-Wahab","year":"2016","journal-title":"PloS One"},{"key":"R14-20230922","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1016\/j.chest.2018.08.1048","article-title":"Immune checkpoint immunotherapy for non-small cell lung cancer: benefits and pulmonary toxicities","volume":"154","author":"Suresh","year":"2018","journal-title":"Chest"},{"key":"R15-20230922","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1378\/chest.12-1467","article-title":"Organizing pneumonia as a side effect of ipilimumab treatment of melanoma","volume":"143","author":"Barjaktarevic","year":"2013","journal-title":"Chest"},{"key":"R16-20230922","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s13045-017-0433-z","article-title":"Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report","volume":"10","author":"Li","year":"2017","journal-title":"J Hematol Oncol"},{"key":"R17-20230922","first-page":"95","article-title":"Organizing pneumonia following treatment with pembrolizumab for metastatic malignant melanoma\u2014a case report","volume":"20","author":"Kuint","year":"2017","journal-title":"Respir Med Case Rep"},{"key":"R18-20230922","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ctarc.2018.02.004","article-title":"Radiologic and autopsy findings in a case of fatal immune checkpoint inhibitor-associated pneumonitis","volume":"15","author":"Shea","year":"2018","journal-title":"Cancer Treat Res Commun"},{"key":"R19-20230922","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40425-016-0117-1","article-title":"Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors\u2014an autopsy study","volume":"4","author":"Koelzer","year":"2016","journal-title":"J Immunother Cancer"},{"key":"R20-20230922","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.2169\/internalmedicine.8271-16","article-title":"Nivolumab-induced acute fibrinous and organizing pneumonia (AFOP)","volume":"56","author":"Ishiwata","year":"2017","journal-title":"Intern Med"},{"key":"R21-20230922","first-page":"168","article-title":"Pembrolizumab-induced pneumonitis with a perilymphatic nodular pattern in a lung cancer patient: a radio-pathologic correlation","volume":"26","author":"Ueno","year":"2019","journal-title":"Respir Med Case Rep"},{"key":"R22-20230922","first-page":"613","article-title":"Teaching monograph. Tissue reactions to drugs","volume":"82","author":"Irey","year":"1976","journal-title":"Am J Pathol"},{"key":"R23-20230922","first-page":"1781","article-title":"Adverse drug reactions: types and treatment options","volume":"68","author":"Riedl","year":"2003","journal-title":"Am Fam Physician"},{"key":"R24-20230922","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/annonc\/mdw443","article-title":"Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab","volume":"28","author":"Menzies","year":"2017","journal-title":"Ann Oncol"},{"key":"R25-20230922","doi-asserted-by":"crossref","first-page":"121","DOI":"10.7326\/M17-2073","article-title":"Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: a systematic review","volume":"168","author":"Abdel-Wahab","year":"2018","journal-title":"Ann Intern Med"},{"key":"R26-20230922","doi-asserted-by":"crossref","first-page":"38S","DOI":"10.1378\/chest.102.1.38S","article-title":"Pathologic aspects of bronchiolitis obliterans organizing pneumonia","volume":"102","author":"Colby","year":"1992","journal-title":"Chest"},{"key":"R27-20230922","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/00000478-198606000-00002","article-title":"Bronchiolitis obliterans and usual interstitial pneumonia. A comparative clinicopathologic study","volume":"10","author":"Katzenstein","year":"1986","journal-title":"Am J Surg Pathol"},{"key":"R28-20230922","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/ajcp\/97.5.669","article-title":"Hyperplasia of type II pneumocytes in acute lung injury. Cytologic findings of sequential bronchoalveolar lavage","volume":"97","author":"Stanley","year":"1992","journal-title":"Am J Clin Pathol"},{"key":"R29-20230922","doi-asserted-by":"crossref","first-page":"119","DOI":"10.21037\/tlcr.2017.04.03","article-title":"Special topics in immunotherapy and radiation therapy: reirradiation and palliation","volume":"6","author":"Evans","year":"2017","journal-title":"Transl Lung Cancer Res"},{"key":"R30-20230922","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3389\/fphar.2018.00185","article-title":"Combining immunotherapy and radiotherapy for cancer treatment: current challenges and future directions","volume":"9","author":"Wang","year":"2018","journal-title":"Front Pharmacol"},{"key":"R31-20230922","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.adro.2018.08.003","article-title":"Toxicity of radiation and immunotherapy combinations","volume":"3","author":"Verma","year":"2018","journal-title":"Adv Radiat Oncol"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000001298","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T23:00:39Z","timestamp":1695423639000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000001298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000001298","relation":{},"ISSN":["0147-5185"],"issn-type":[{"value":"0147-5185","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]}}}